广州安必平医药科技股份有限公司关于合计持股5%以上股东权益变动触及1%刻度的提示性公告

Group 1 - The core point of the announcement is that shareholders of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd. have reduced their holdings, triggering a change in equity that touches the 1% threshold [1][3]. - The shareholders involved in the equity change include Zhuji Gaotejia Ruian Investment Partnership, Chongqing Gaotejia Ruian Equity Investment Fund Partnership, Hangzhou Gaotejia Ruihai Investment Partnership, Hangzhou Ruihong Investment Partnership, and director Wang Haijiao [3]. - From December 1 to December 30, 2025, the shareholders collectively reduced their holdings by 685,772 shares, which is 0.73% of the total share capital, decreasing their total holdings from 6,292,662 shares to 5,606,890 shares, representing a change from 6.73% to 5.99% of the total share capital [3]. Group 2 - This equity change is part of a previously disclosed reduction plan by the shareholders and does not trigger a mandatory tender offer [3]. - The equity change will not result in a change of the company's controlling shareholder or actual controller [3]. - The company will continue to monitor the shareholders' compliance with the reduction plan and will ensure timely disclosure of relevant information to investors [3].